Telaprevir

PBAC's latest decision on Telaprevir: Recommended with restriction (2012). Considered for Treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment naïve or have previously been treated with interferon based therapies.

Eligible population

Treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment naïve or have previously been treated with interferon based therapies.

Therapy area

Hepatology

Line of therapy

Second-line | Later-line

Evidence base

RCT

Primary endpoint

SVR24

Key trials

ADVANCE, PROVE 1, PROVE 2, Kumada 2011, ILLUMINATE

Comparator

peginterferon alfa and ribavirin alone for 48 weeks

Economic model

CUA

ICER note

ICER not stated in the provided text. Economic analysis section begins but is incomplete in the excerpt provided.

ICER (historical)

$15k/QALY–$45k/QALY in an earlier submission (2011) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

Submission history

• Nov 2011: Noted — ICER $45k/QALY
• Mar 2012: Recommended with restriction
• Jul 2012: Recommended with restriction